The latest announcement is out from C4 Therapeutics ( (CCCC) ).

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated ...

C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM ... additional detail on the company’s planned next steps of clinical development. C4 Therapeutics (C4T) ...

Investing.com -- C4 Therapeutics (NASDAQ:CCCC) stock rose 13% Monday after Stephens analyst Sudan Loganathan upgraded the company from Equal Weight to Overweight with a price target of $6.00, ...

Newcomers to chess should consider learning the following openings to ensure they get off to a good start as both White and ...

Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...

A new Michigan study is showing changes in the number of people dying from opioid overdoses and the branching positive ...

As they explained in their case report in the Journal of Neurology and Neuroscience, ophthalmologic examination identified ...

America’s Trident D5 missiles represent a bedrock of America’s national defense—meaning that they must occasionally be tested ...

Investing.com -- Barclays has identified several promising opportunities in the Oncology and Inflammation & Immunology (I&I) sector, highlighting companies with innovative protein degradation ...

India’s private defence companies are poised to sustain strong momentum, clocking 16-18% revenue growth in the current fiscal ...

Baystreet.ca News Commentary – Recent cuts to public cancer research funding are reshaping the oncology landscape as ...